Large-scale GWAS meta-analysis of serum antibody levels in healthy individuals reveals distinct genetic architectures

Thomas W. Willis[1,4], Effrossyni Gkrania-Klotsas[2,3], Nicholas J. Wareham[2], Eoin F. McKinney[4,5], Paul A. Lyons[4,5], Kenneth G.C. Smith[6,7], and Chris Wallace[1,4,5]

[1]Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK
[2]Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK
[3]Department of Infectious Diseases, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
[4]Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK
[5]Department of Medicine, University of Cambridge, Cambridge, UK
[6]Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
[7]Department of Medical Biology, University of Melbourne, Melbourne, Australia
* tom.willis@live.com; cew54@cam.ac.uk

Abstract

Antibodies are the principal effector proteins of humoral immunity. Dysregulated antibody production is a feature of a number of heritable immune-mediated diseases, such as the antibody deficiencies and IgA nephropathy. To characterise the common-variant architecture of serum antibody levels in the general population, we conducted the largest GWAS meta-analyses to date of serum IgA, IgM, and IgG, attaining sample sizes of 85,204, 55,368, and 58,777, respectively. We identified 82 novel associations across three isotypes, including 38 novel IgA associations (of a total of 77), 36 novel IgM associations (of a total of 82), and 8 novel IgG associations (of a total of 14). We found that isotype-specific genetic architecture was largely disjoint with few signals colocalising across isotypes in spite of their overall positive genetic correlation. We identified a large number of colocalisations between antibody phenotypes and immune-mediated diseases, and 16 between antibody phenotypes and a lymphocyte count phenotype. We report a greatly expanded catalogue of serum antibody-

29   associated variants and characterise these in terms of their pathway context and relation to

30   immune pathology.

Introduction

Antibodies are soluble immunoglobulins which form the basis of humoral immunity. They are

antigen-binding effector proteins responsible for the neutralisation of pathogens and toxins,

opsonisation, and the activation of complement. Immunoglobulins exist also as the membrane-

bound antigen-binding moiety of cell-surface B-cell receptors (BCRs). In both guises,

immunoglobulins are distinguished by the great diversity of antigen-binding affinities they

provide to the adaptive immune system, together with T-cell receptors. This diversity depends

upon extensive germline polygeny and polymorphism at the *IGH*, *IGK*, and *IGL* loci. This

germline-encoded variation is supplemented by somatic hypermutation in the germinal centre.

In addition to its contribution to antibody repertoire diversity, germline genetic variation also

contributes to interindividual variation in the quantity of serum antibody produced (1). Heritable

influences on antibody production have long been studied in the setting of disorders of antibody

production: these include antibody deficiencies, such as Bruton's agammaglobulinaemia (2) and

common variable immunodeficiency (3), and hypergammaglobulinaemias, in which there is an

excess of antibody production, such as the 'hyper IgM' syndromes (4). Family-based studies in

healthy individuals have produced evidence of a substantial heritable component to antibody

production (1,5) and the advent of genome-wide association studies (GWAS) has allowed

discovery of common variants underlying this heritability (6–9).

Antibody dysfunction and the dysregulation of antibody production feature prominently in the

pathogenesis of certain diseases such as IgA nephropathy, IgA vasculitis, and the

aforementioned antibody deficiencies. Study of the common-variant architecture of antibody

production in healthy individuals can inform understanding of the genetic basis of these

diseases (6,10) as well as variation in the response to vaccination in the population at large. In

this work we investigate this genetic architecture with two new GWAS of serum IgG and IgM,

and large-scale meta-analyses of IgG, IgM, and IgA. We greatly increase the number of

common-variant associations, and report updated estimates of serum antibody level heritability,

and the genetic correlation of isotypes with one another and immune-related traits. We find,

contrary to our expectation and to positive phenotypic and genetic correlations overall, that the

majority of significant signals detected in these large meta-GWAS are isotype-specific.

Material and methods

GWAS of serum IgG and IgM in the EPIC Cohort

We performed GWAS of serum IgG and IgM in 7,946 and 8,008 individuals, respectively.

Participants were drawn from the European Prospective Investigation into Cancer (EPIC)-

Norfolk Study (https://doi.org/10.22025/2019.10.105.00004). The study was carried out

according to the principles of the Declaration of Helsinki, participants provided informed

consent, and the study was approved by the Norwich Local Research Ethics Committee. The

GWAS were performed using the methodology described previously in our study of serum IgA in

EPIC (10). Briefly, IgG and IgM were quantified using immunosorbent assay; IgG was measured

as the sum of the IgG1, IgG2, IgG3, and IgG4 subclasses. Serum antibody measurements were

log-transformed and mean-centered. GWAS was performed for each isotype using an additive

model in SNPTEST (v2.5.4-beta3) incorporating age, sex, and scores on the first ten genetic

principal components.

75 Acquisition of public GWAS data sets

We downloaded immunoglobulin GWAS summary statistics (6,11–14) from the EBI GWAS

Catalog where available or from URLs provided in individual publications (Supplementary Table

1). Summary statistics from the Eldjarn study were available both with and without median

normalisation; we chose to use median-normalised datasets to match the median normalisation

of the Pietzner datasets. Liu et al. published two versions of their IgA meta-analysis

distinguished by the inclusion or exclusion of data from a study of serum IgA in the deCODE

cohort (15). To prevent the inclusion of samples overlapping with those in the Eldjarn study in

our own meta-analysis, we used the Liu meta-analysis excluding the deCODE data.

GWAS summary statistics for immune-related traits and diseases (7,16–27) were downloaded

from the URLs in Supplementary Table 2.

87 Harmonisation and standardisation of GWAS data sets

Prior to downstream analysis, we processed those GWAS datasets which were not available in

a harmonised format from the GWAS Catalog with version 1.1.10 of the EMBL-EBI GWAS

summary statistics harmoniser (28). This process lifted over variant coordinates to the GRCh38

assembly, inferred the strand orientation of palindromic variants, and aligned alleles to the

Ensembl 95 reference.

The phenotypic values used to produce each GWAS dataset were subject to transformation and

standardisation by their respective authors, but the method chosen differed between studies

(Supplementary Tables 1 and 3). These differences produced phenotypic values, and therefore

effect estimates and standard errors, on different scales. To correct for this we estimated the

standard deviation of the phenotype in each dataset, exploiting the following relationship

between phenotypic variance *var(Y)*, genotypic variance *var(X)*, the sample size *n*, and the

variance of the effect estimate *var(β)*:

$$var(\beta) \cong \frac{var(Y)}{n * var(X)}$$

where genotypic variance is given by:

$$var(X) = 2 * f * (1 - f),$$

with *f* the minor allele frequency estimated using 1kGP European samples. We regressed *n* *

var(X) on the reciprocal of *var(β)* and obtained an estimate of *var(Y)* as the regression slope.

We conducted 10 replicates of this regression in each dataset using 10,000 SNPs randomly

selected after LD pruning using *PLINK* version 2.00a5.10 (29,30) with a 1,000 kb window, a

step size of one, and $r^2 < 0.2$. The estimate thus obtained was stable across replicates

(Supplementary Table 3). We used the square root of the median of the estimates thus

obtained as the estimated standard deviation, which we used in turn as a scaling factor to divide

effect estimates and standard errors in each dataset prior to meta-analysis. Our application of

this method of standardising summary statistics assumes homogeneity of the underlying

phenotype variance across component GWAS; in the absence of phenotype data from these

studies, it was not possible to evaluate this assumption.

We did not apply a genomic control correction nor an LDSC intercept correction to the standard

errors of the input GWAS nor our final meta-analyses (31).

GWAS meta-analysis

We performed an outer join between the SNPs of each GWAS for each antibody isotype and

then a fixed-effect, inverse variance-weighted meta-analysis.

We designated as candidate 'lead SNPs' those variants which had a p-value $< 5 \times 10^{-8}$ and the

smallest p-value in the 1Mb interval centered upon the variant. We visually inspected the

surrounding 4Mb interval using *locuszoomr* (32) and excluded lead SNPs which appeared to be

in LD with a more significantly associated SNP. Estimates of r^2 reported between pairs of

variants in the text were obtained from 1kGP European samples using the LDlink web

application (33).

In order to identify novel associations, we downloaded known associations reported in the EBI

GWAS Catalog on February 4th 2025 [28]. We added associations from the GWAS performed by

Gudjonsson et al. (34), which we omitted from our meta-analyses due to the possibility of

sample overlap with the Icelandic deCODE cohort studied by Eldjarn et al. For IgA, we added

associations reported in Table 2 of the study by Liu et al. after lifting them over to GRCh38 and

the associations we reported in our earlier meta-analysis of IgA (10). Lastly, we added

associations present in the studies included in our meta-analyses, excepting the studies of IgG

and IgM in the EPIC Cohort which we publish here for the first time. For each of our isotype-

specific meta-analyses, we then merged the list of lead SNPs from signals attaining genome-

wide significance with our compiled list of known associations using an 'overlap join': where no

existing association's reported lead SNP lay within 500kb window up- or downstream of the lead

SNP in our own meta-analysis, we designated the latter as a novel association.

We downloaded the 2024 edition of the IUIS' classification table of inborn errors of immunity

(35) from the IUIS website (https://iuis.org/committees/iei/) and obtained the HGNC symbol and

coordinates of the genes listed in this table from Ensembl using biomaRt (36,37). We mapped

SNPs to IEI genes which lay within 200kb.

Estimation of trait heritability and the genetic correlation

We used the *SumHer* component of *LDAK* version 5.1 to estimate heritability and the genetic

correlation between traits (38). We used the 'Human Default' heritability model when estimating

the trait heritability, and the 'LDAK-Thin' heritability model and 'SumHer-GC' model of

confounding when estimating the genetic correlation.

We identified highly significant and possibly spurious association signals in the *IGH* and *IGK* loci

(Results). We removed these loci (chromosome 14, positions 105,586,437 to 106,879,844, and

chromosome 2, positions 88,857,361 to 90,235,368 in the GRCh38.p14 assembly, GenBank

Gene IDs 3492 and 50802, respectively) and the *IGL* locus (chromosome 22, positions

22,026,076 to 22,922,913, GenBank Gene ID 3535) for the purposes of heritability and genetic

correlation estimation. For the *IGH* and *IGK* loci, it was necessary to exclude a larger region,

103,000,000 to 107,00,000 and 88,700,000 to 90,235,368, respectively to fully ablate the

association signals. We report heritability and genetic correlation estimates with and without

inclusion of these loci.

We also report heritability estimates with and without inclusion of the major histocompatibility

locus (MHC), which we defined liberally as the interval on chromosome 6 between positions

24,000,000 and 45,000,000. The MHC was excluded from datasets for the purpose of genetic

correlation estimation.

We estimated the phenotypic correlation of isotype-specific serum antibody levels using data

from the EPIC Cohort. We used Pearson's correlation for isotype pairs using both raw and log-

transformed data, and calculated bootstrap confidence intervals for each estimate using 1,000

replicates.

We used SNP genotype data from 535 European-ancestry samples from the Phase 3 release of

the 1000 Genomes Project (1kGP) (39) for out-of-sample estimation of the squared correlation

of SNP genotypes (*i.e.* r^2) and the calculation of *SumHer* SNP taggings. All but one GWAS used

in our analyses were performed in European-ancestry cohorts (Supplementary Table 1). The

exception, the serum IgA meta-analysis of Liu et al. which combined 16 ancestry-defined

cohorts spanning European, African, East Asian, and admixed ancestries, nonetheless

consisted largely of European-ancestry individuals (35,094 of 41,263, ~85%). We therefore

identified 1kGP European-ancestry samples as the most suitable reference panel.

We downloaded data from the high-coverage GRCh38 1kGP release (40) and processed it

using *PLINK* version 2.00a5.10 to meet the following criteria: SNPs only; MAF > 0.005;

missingness per SNP < 0.01; missingness per sample < 0.01; exact test of Hardy-Weinberg

equilibrium has p-value > 1e-50. We enforced alignment of reference and alternative alleles to

the GRCh38 reference sequence.

186   Annotation of GWAS lead SNPs

We assigned possible causal genes to each lead SNP using the Open Targets Platform (41)

and Ensembl version 113 (42). Genes were assigned to a variant if the variant was missense in

the gene or if the variant was in the fine-mapping credible set for any molecular QTL for the

gene. For lead variants with no gene thus assigned, we assigned the nearest gene identified

using Ensembl annotations. We then performed pathway analysis to identify biological pathways

related to these genes as a whole, and colocalisation between the different antibody

phenotypes, with a lymphocyte count phenotype, and with a set of 13 immune-mediated

diseases, as detailed below.

Pathway analysis

To identify biological pathways highlighted by our genetic associations, we first created a test set of genes from the union of possible causal genes across our meta-analyses of IgA, IgG and IgM. We then used the *enrichKegg* function from version 4.14 of the *clusterProfiler* package (43), and the *enrichPathway* function from version 1.50.0 of the *reactomePA* package (44) to test for association with pathways annotated by KEGG and Reactome, respectively.

Colocalisation

We carried out colocalisation analysis using the *coloc::coloc.abf* function in *coloc* version 5.2.4 (45). In accordance with package defaults we defined the prior probability of a random SNP's being causal for one trait in a pair but not the other as 1×10^{-4} and the prior probability of a random SNP's being jointly causal for both traits as 1×10^{-5}. We identified candidate serum antibody loci for colocalisation by searching for pairs of lead SNPs for distinct isotypes which lay within 1Mb of one another. For each pair of lead SNPs thus identified, we included in the analysis all SNPs lying in the interval between the lead SNPs as well as those in the 250kb flank regions lying up- and downstream of the same interval. For colocalisation of loci for serum antibody and non-serum antibody traits, we searched a 1Mb interval centered on each serum antibody lead SNP for SNPs reaching genome-wide significance ($p < 5 \times 10^{-8}$) for the non-antibody trait. Where such SNPs were present, we carried out colocalisation using the SNPs in the 1Mb interval. We examined regions where the posterior probability of a shared causal variant exceeded 0.5 using the *coloc::plot_extended_dataset* function, and designated colocalisations on the basis of the posterior probability of a shared causal variant, the posterior odds of the same hypothesis, and the visible concordance of the association signal in each

GWAS. The smallest posterior probability of colocalisation for a locus thus identified as the site

of a colocalisation was 0.69.

Our serum antibody meta-analyses incorporated multiple studies which differ in the panel of

SNPs for which they reported summary statistics. As a consequence, the sample size of each

meta-analysis varied across SNPs. Approximate Bayes factors do not account for sample size

imbalance of this kind (46) and the resulting miscalibration of fine-mapping (47) may propagate

to colocalisation analysis. We conducted a sensitivity analysis, filtering the SNPs included in

colocalisation analysis by their sample fraction, *i.e.* the SNP-specific sample size expressed as

a proportion of the largest sample size in the meta-analysis. We retained only those SNPs for

which the sample fraction in each meta-analysis differed by no more than 0.1. We found that

filtering rarely affected the reported posterior probability of a shared causal variant, with two

exceptions (Supplementary Figures 1); one of these exceptions, the association signal for IgG

and IgA at *TNFSF13*, saw the posterior probability of a shared causal variant differ by ~1

between the filtered and unfiltered datasets (Supplementary Figures 2 and 3). We disregarded

this locus from further consideration as the site of a colocalisation.

235 Results

236 We conducted fixed-effect, inverse variance-weighted meta-analyses of IgG, IgM, and IgA

237 datasets (Figure 1, Supplementary Table 1), attaining sample sizes of 55,368, 58,777, and

238 85,204, for these isotypes, respectively.

Figure 1. Manhattan plots of GWAS p-values for the meta-analyses of serum IgA (A), IgG (B), and IgM (C). The serum IgA meta-analysis comprised 85,204 samples, the IgG meta-analysis 58,777, and the IgM meta-analysis 55,368. Association signals in the *IGH* region have been omitted for the reason of the large scale of their p-values relative to those in other association signals.

Both the antibody-based EPIC study and aptamer-based Pietzner and Eldjarn GWAS of serum

IgA and IgG featured genome-wide significant association signals centered upon the constant

region of the *IGH* locus. The serum IgA GWAS replicated the known association of the *IGHA1*

missense variant, rs117775520, with serum IgA (15), although the direction of effect differed

between the EPIC GWAS and the aptamer-based GWAS (Supplementary Figure 4 and

Supplementary Table 4). Variants in the locus were associated with serum IgG in the EPIC,

Pietzner, and Eldjarn GWAS but the location of the lead SNP differed substantially between

EPIC and the other datasets (Supplementary Figure 5). The Eldjarn GWAS of serum IgM

identified a significant but more modest association with rs10873559, near *IGHA1*

(Supplementary Figure 6). rs232230, a missense variant in *IGKC*, was associated with serum

IgG in the Eldjarn study (Supplementary Figure 7). In our meta-analyses, all three isotypes had

associations with variants in the *IGH* locus (Supplementary Figure 8) whereas only IgG and IgA

had significant associations in the *IGK* locus (Supplementary Figure 9).

We could not definitively account for the differing locations and effect directions estimated at

IGH variants in the serum IgA and IgG GWAS. We hypothesised that coding variation within

them (e.g. rs117775520) could modify the immunoglobulin epitopes bound by the capture

antibodies and aptamers used in affinity-based quantification, and thus induce spurious

genotype-dependent variation in antibody measurement. The immunoglobulin allotypes defined

by certain coding variants were originally characterised in terms of their differing reactivity to

immunologic reagents (48) and recent work has shown IgG1 allotypes do indeed affect

detection by commercially available anti-IgG1 antibodies (49). We therefore took a conservative

approach, and removed the *IGH*, *IGK* and *IGL* regions from some primary analyses that follow.

We report heritability and genetic correlation estimates with the inclusion of these regions for

sensitivity purposes.

Outside of the *IGH* and *IGK* loci, we identified 14 associations with serum IgG, of which 8 were

novel (Supplementary Table 5), 82 associations with serum IgM (36 novel, Supplementary

Table 6) and 77 associations with serum IgA (38 novel, Supplementary Table 7), making for a

total of 82 novel associations across all three isotypes (Table 1). We obtained heritability

estimates for each isotype using these data (Supplementary Table 8), finding larger estimates

for IgA ($h^2 = 0.16$) and IgM ($h^2 = 0.21$) than for IgG ($h^2 = 0.07$). Inclusion of the *IGH*, *IGK*, and

IGL regions increased serum IgG heritability markedly (21.8%), and IgA and IgM heritability

modestly (1.5% and 1.6%). We also examined the influence of the major histocompatibility

complex (MHC) upon heritability estimates. The MHC features long-range LD patterns and

typically evinces strong genetic associations with immune-related traits; SNPs in the MHC

featured associations with all three isotypes in our meta-analyses (Figure 1). Inclusion of the

MHC increased estimated IgM heritability the most (22.7%), and had an appreciable effect on

IgA (11.0%) and IgG (16.6%), also.

All serum immunoglobulin measures were positively correlated on the log scale (Supplementary

Table 9). Concordant with this finding were significant positive genetic correlation (r_g) estimates

between serum IgA and IgG, and IgG and IgM, when the *IGH*, *IGK*, and *IGL* loci were excluded

(Table 2 and Supplementary Table 10). These r_g estimates were reduced in magnitude and

made non-significant with inclusion of the *IGH*, *IGK*, *IGL* loci. We attribute this to the potential

false positive results in the *IGH* locus sufficing to dilute evidence of pleiotropy in the rest of the

genome as measured by the genetic correlation.

First isotype	Second isotype	Genetic correlation estimate	Standard error	p-value
IgA	IgM	-0.03	0.03	3.51E-01
IgA	IgG	0.21	0.04	6.10E-07
IgG	IgM	0.15	0.05	1.18E-03

Table 2. Estimates of the genetic correlation between serum antibody isotype levels. p-values
were calculated from a chi-squared test of non-zero genetic correlation. The MHC and *IGH*,
IGK, and *IGL* loci were excluded from the datasets used to produce these estimates.

In spite of the genetic correlation we observed when omitting these loci, however, we found only

one locus at which there was strong evidence of a causal variant shared between IgG and IgA

(Supplementary Figure 10; posterior probability of colocalisation, 'PPC', 0.85), and none at

which this was true for IgG and IgM (Supplementary Table 11). This may be explained in part by

the much smaller number of IgG associations, consistent with its relatively lower heritability

estimate (Supplementary Table 8).

In contrast, although IgA and IgM did not show significant genetic correlation overall, six

associations with each isotype showed evidence of a causal variant common to both isotypes in

colocalisation analysis (Supplementary Table 11, Supplementary Figures 11-16, minimum PPC

= 0.80). For five of these colocalising associations, the direction of effect on serum IgA and IgM

was concordant. The exception was on chromosome 4 near *RHOH,* for which association the

IgA and IgM lead SNPs had discordant effects on the level of each isotype. *RHOH* encodes the

haematopoiesis-specific RhoH GTP-binding protein (50) and mutations in the gene cause an

autosomal recessive combined immunodeficiency (51). RhoH-deficient mice show normal IgM

production but impaired production of class-switched IgG1 in response to immunisation with T

cell-dependent antigen (52), suggesting the *RHOH*-mapped variants may affect serum antibody

levels through an impact on the efficiency of class switch recombination. A combination of

shared signals, some with the same effect direction (immunoglobulin production) and others

with the opposite (class switching efficiency), could explain the lack of overall genetic correlation

between these isotypes.

The colocalising associations with concordant direction of effect included a novel association

with IgA (lead SNP rs2872516) which colocalised with a known association of the same locus

with IgM (rs4795397, PPC = 0.95). However, another novel association with IgG (rs17676923)

in this region appeared to relate to a distinct causal variant with a posterior probability of distinct

causal variants of ~1. This was supported by an examination of LD in the region which showed

that the lead SNPs for IgA and IgG were not in LD (r^2 = 0.03), although those for IgA and IgM

were (r^2 = 0.83). All three SNPs belong to eQTL credible sets for *GSDMA*, *GSDMB*, and *IKZF3*

in blood.

Given the overlap of association signals, we used pathway analysis to summarise the

associations seen across all isotypes. This identified six and ten significant KEGG and

Reactome pathways, respectively (q-value < 0.05, Figure 2), the most prominent amongst them

relating to B cell receptor and NF-kB signalling. Our gene selection strategy was deliberately

broad, which sometimes leads to the nomination of multiple genes for a single association. By

comparing this list of genes with the list of genes in associated pathways we can highlight more

likely causal genes in some cases (Supplementary Figure 17). Of note, we see that the

associated pathways typically contain associations with more than one isotype, highlighting the

convergent biology of the GWAS associations in spite of the limited evidence of shared signals.

Figure 2. Significant (q-value < 0.05) pathways in (a) KEGG and (b) Reactome pathway
analysis of the union of potential causal genes nominated for any isotype. The 'fold enrichment'
is given by the 'ratio of the frequency of input genes annotated in a term to the frequency of all
genes annotated to that term' (90).

In a few cases, we were able to relate the genes of isotype-specific associations to isotype-
specific biology. We mapped the IgM-associated SNP rs614004 to *CMTM7*, which encodes a
membrane protein important in the development of innate-like B1 cells which principally secrete
constitutive, 'natural' IgM (53). We mapped associations for both IgA and IgG (i.e. class-

switched isotypes), but not for IgM, to *TRAF3*, which encodes a regulator of class switch

recombination (54). We linked the IgA-specific association on chromosome X to *C1GALT1C1*,

essential for the O-glycosylation of IgA1 (the predominant IgA subclass in serum) and

previously identified in a GWAS of galactose-deficient IgA1 (Gd-IgA1), an important IgA

nephropathy endophenotype (55). *ST3GAL1*, another IgA-specific gene, encodes an enzyme

also participating in O-glycosylation of IgA1. A recent GWAS of Gd-IgA1 also identified *DERL3*,

a gene in which we report a missense variant associated with serum IgA and which participates

in the processing of misfolded proteins (56). Despite studying a serum IgA phenotype, we also

mapped an IgA-specific association to *LTBR*, essential for the development of Peyer's patches,

the site of secretory IgA production in the small intestine (57).

As antibodies are secreted by plasma cells and plasmablasts derived from B cells, we

hypothesised that some signals may relate to B cell abundance. Whilst we could not find any

sufficiently large GWAS of B cell count for use in colocalisation, total lymphocyte count has

been studied in large cohorts, and we used one such GWAS as a proxy (27). We found a

modest but significant genetic correlation between serum IgA and lymphocyte count (r_g = 0.09, p

= 3 x 10^{-4}). Whilst r_g estimates for IgM and IgG were not significant, we conducted colocalisation

analyses for all three isotypes with lymphocyte counts as r_g had not proved a dispositive

indicator of cross-isotype colocalisation.

We found 16 loci with moderate to strong evidence of a shared causal variant for serum

antibody and lymphocyte count phenotypes (Supplementary Table 12): nine for IgA, six for IgM

and one for IgG (minimum PPC = 0.69), including the above-mentioned signal near *GSDMB*,

which colocalised with both IgA and IgM. However, the directions of effect were not consistent:

higher immunoglobulin levels were associated with higher lymphocyte counts in eight cases and

with lower lymphocyte counts in the other eight. This explains the lack of detectable genetic

correlation, which is a genome-wide measure. Our interpretation of the ostensibly paradoxical

relationship in the latter eight cases is hampered by the lack of B cell-specific data. Given

lymphocyte count is the sum of B, T, and natural killer cell counts, an increased total lymphocyte

count could arise from the production of more B cells, or fewer in the context of more T cells, or

a change in T- or natural killer cell count absent any change in B-cell count.

All isotypes showed significant genetic correlation with two or more immune-mediated diseases

(IMDs), amounting to nine significant estimates (Supplementary Table 13). These were positive

with the exception of a negative genetic correlation between IgG and asthma (r_g = -0.1). We

observed the strongest correlation between serum IgA and IgA nephropathy (r_g = 0.33),

replicating published work (6). Inclusion of the *IGH*, *IGK*, and *IGL* loci made no nominally

significant difference to antibody-immune disease genetic correlation estimates as assessed by

z-test.

Several loci well-known for their association with IMDs colocalised with serum antibody signals,

bolstering the evidence for the biological salience of the associations identified in our meta-

analyses (Supplementary Figure 12). IgA associations signals at the *IL7R*, *INAVA*, *UBE2L3*,

and *IL2RA* loci colocalised with three to five IMDs each (minimum PPC = 0.72) and, with one

exception, SNP effects were positively correlated between the serum IgA and IMD phenotypes.

We observed antibody-IMD signal colocalisation at the aforementioned *GSDMB* locus for eight

isotype-IMD pairs (minimum PPC = 0.76), including all three studied isotypes. The IgM

association signal centered upon the *PTPN22* missense variant rs2476601 colocalised strongly

with those of rheumatoid arthritis, type 1 diabetes, Crohn's disease, systemic lupus

erythematosus, and hypothyroidism (minimum PPC = 1.0), IMDs whose association with this

mutation is well-known (20,24,58). In general we observed that the direction of effect for serum

antibody- and IMD-associated SNPs was neither consistently concordant nor discordant

(Supplementary Figure 18). IgA nephropathy was exceptional in this regard: all four of its

signals colocalising with serum IgA (minimum PPC = 0.86) showed positively correlated effects

across the locus and at the lead SNP. Two of these signals mapped to the genes *TNFSF13* and

TNFRSF13B, the APRIL-TACI receptor-ligand pair, and a third mapped to another TNF family

member, *TNFSF8*; all three genes are implicated in B-cell biology.

68 of our associations were in or near known genes associated with inborn errors of immunity

(IEIs); 32 of these associations were novel (Supplementary Table 14). With the exception of the

more common antibody deficiencies, IEI phenotypes do not admit formal colocalisation analyses

for want of summary statistics and evidence of common-variant architecture. For IgM, these

associations included variants in *CARD11*, *LYN*, and *CIITA* as well as rs12554596, an intronic

variant in and eQTL for *PAX5*, which encodes a transcription factor and 'master regulator' of B

cell development (59). A single case of PAX5 deficiency is known, featuring B-cell

lymphopaenia and hypogammaglobulinaemia (60). In two cases, variants associated with IgA

and IgM appeared to represent distinct causal variants (on the basis of low LD and *coloc*

favouring the distinct causal variant hypothesis) but both variants were linked to the same gene.

IgM-associated rs290243 and IgA-associated rs4744011 are not in LD (r^2=0.18), yet both

belong to eQTL credible sets for *SYK* in NK cells and monocytes, respectively. *SYK* encodes a

non-receptor tyrosine kinase which participates in BCR signalling (61) and in which gain-of-

function mutations cause an autoinflammatory disorder (62). Similarly, rs6589225 and

rs4938518 were associated with IgM and IgA respectively. Again, we observed these to be in

low LD (r^2=0.28) whilst belonging to eQTL credible sets for the same gene, *POU2AF1*. A loss-

of-function mutation in *POU2AF1* has been observed to cause an autosomal recessive, CVID-

like antibody deficiency, BOB1 deficiency, in one patient (63).

Other notable associations include IgA with rs1585213, an intronic variant in *NFKB1*, which

encodes NF-κB, a critical immune regulator downstream of TLR and B-cell receptor (BCR)

signalling and integral to development of the humoral response (64). Loss-of-function mutations

in *NFKB1* have been identified as the most common cause of common variable

immunodeficiency (65), an antibody deficiency characterised by IgG deficiency alongside IgA

and/or IgM deficiency; IgA is absent in a majority of patients (66) . Similarly, rs6890853 belongs

to e-, s-, and pQTL credible sets for *IL7R*/*IL7R*▯, whose expression and signalling is important

in the early stage of B-cell progenitor development. Loss-of-function mutations in *IL7R* cause

the B cell-positive severe combined immunodeficiency IL7R deficiency (67).

444
Just as our pathway analyses linked association-related genes to B-cell biology, we could relate

many individual novel antibody associations to the same. We found three novel IgA associations

featuring missense variants in B cell-related genes. rs13388394 is located in *RASGRP3*, which

encodes a guanine nucleotide exchange factor and RAS activator. Its murine orthologue

Rasgrp3 contributes to B-cell receptor-induced Ras activation and the deletion of *Rasgrp3* leads

to deficient production of certain IgG subclasses (68). rs113495277 is a missense variant in

TRAF1. TNF receptor associated factor 1 (TRAF1) forms multimeric complexes with TRAF2

which bind to the cytoplasmic domain of CD40 (the cell-surface receptor for the costimulatory

ligand CD40L) upon ligation and activate the canonical NF-κB signalling pathway (69,70).

454
rs3177243 is a missense variant in *DERL3*, a gene recently associated with B cell activation

and differentiation, and the unfolded protein response (71). Its association with the latter may

explain its expression in plasma cells given their burden of secretory protein synthesis;

rs3177243 is also associated with an IgG N-glycan phenotype (72) and non-albumin serum

protein levels (73). We also identified a novel IgM-associated missense variant, rs11666267, in

NIBAN3, which encodes B cell novel protein 1, a regulator of BCR signalling (74).

Other variants were linked to genes involved in B cell-related malignancies. This included two

IgA-associated variants, rs55901664 and rs17505102, which were intronic to the genes

TBL1XR1 and *TP63*, respectively. Somatic mutations in *TBL1XR1* cause impaired plasma cell

differentiation and a bias towards the production of immature memory B cells in aggressive B

cell lymphomas (75), while *TP63* is known to participate in somatic gene fusion events with

TBL1XR1 in a small minority of diffuse large B-cell lymphomas (76).The IgG-associated variant

rs184552867 is an intronic variant in *PRDM11* which has been identified as a tumour

suppressor gene in B cells and which may be downregulated in diffuse large B-cell lymphoma

(77).

471 Discussion

The *IGH* and *IGK* loci encode immunoglobulin chains and are expected to be of central

importance in a genetic analysis of serum antibody production. Indeed, germline variation within

these loci has known effects upon the antibody repertoire and disease liability (78–81).

However, the large and (within isotypes) discordant directions of effect we observed for serum

IgG and serum IgA at the *IGH* locus suggest an artefactual epitope effect, particularly for the

missense variant rs117775520.

As we cannot confidently report estimates obtained in these loci, we believe that the heritability

estimates (and genetic correlation estimates derived from them) reported without the inclusion

of the *IGH*, *IGK*, and *IGL* loci, and without the MHC, are more reliable. These estimates are also

valuable in their own right as measures of the partial heritability of these traits attributable to

genetic variation outside these important regions. We note that SumHer's heritability estimation

procedure depends upon a random effects model unsuited to isolated large effect sizes and the

extreme LD seen in these regions. We saw an appreciable increase in estimated heritability with

inclusion of the MHC, albeit calculated naively. Using long-read sequencing to improve

resolution in the *IGH*, *IGK*, and *IGL* regions (82) together with more sophisticated analysis will

be required for accurate determination of the heritability they explain in serum antibody levels.

As we mapped strong signals to immunoglobulin heavy chain genes encoding distinct IgA and

IgG subclasses (rs117775520 in particular is a missense variant in *IGHA1*), subclass-specific

GWAS combined with long-read sequencing might provide the multimodal increase in resolution

necessary to better understand these associations.

We detected positive phenotypic and genetic correlations between antibody isotypes but limited

overlap in their individual association signals. This suggests that our cross-isotype genetic

correlation estimates are driven by shared variant effects which do not achieve genome-wide

significance despite our large sample sizes. Our list of associations thus remains an incomplete

catalogue of the common-variant determinants of serum antibody production; we also report a

SNP heritability estimate for serum IgA (0.18) which falls far short of the heritability estimate

obtained from a past twin study (0.50) and the SNP heritability estimate (0.31) obtained in the

same twin cohort (5). The effects we did detect reflect both known and novel biological

mechanisms impacting immunoglobulin secretion, including B-cell progenitor development,

antibody production and class switching, and the role of helper T cells in stimulating

immunoglobulin production. Despite comparably-sized samples for IgG and IgM, we detected

far fewer associations for the former and estimated its heritability to be around one third of the

latter's.

Outside of the *IGH*, *IGK*, and *IGL* loci, we do not believe technical effects can account for the

lack of cross-isotype colocalisation. Each of our meta-analyses incorporated samples both from

GWAS using immunoassays and those using aptamer-based assays. The composition with

respect to assay type was similar for IgG and IgM: 79% and 84% came from aptamer-based

studies for IgG and IgM, respectively, and 14% from immunoassay-based studies for both. The

proportion of samples taken from immunoassay-based studies (35%) was higher for IgA, and

that taken from aptamer-based studies (54%) lower, because of our inclusion of the

immunoassay-based study by Liu et al. We believe it is unlikely that differences in sample

composition between isotypes could introduce locus-specific biases in colocalisation outside of

the immunoglobulin chain loci and in the face of the evidence of average genome-wide shared

signal our genetic correlation estimates represent. More plausible is the possibility that the

aggregation of IgG subclasses obscures subclass-specific colocalisations with IgM and IgA.

Given recent evidence of IgG subclass-specific genetic architecture (80), a possible explanation

for the smaller number of IgG associations we report is that the larger number of IgG

subclasses (four compared with IgA's two and IgM's lack thereof) and our aggregation of them

into one phenotype may have acted to dilute subclass-specific association signals. Future work

could extend IgG and IgA subclass-specific GWAS to the same large scale as the meta-

analyses we present here to clarify the subclasses driving the associations we report.

We found evidence of common-variant architecture shared between antibody phenotypes and

immune-related traits. For the latter we observed multiple colocalisation signals indicative of

shared causal variants in the absence of strong genetic correlation between lymphocyte count

and the antibody phenotypes. Our expectation of straightforward concordance between

antibody and lymphocyte count effect directions was refuted by the lack of a clear relationship.

We observed the same inconsistency in effect direction across antibody signals colocalising

with immune-mediated disease signals. These results suggest that immunoglobulin levels are

not themselves on the causal path for any of these diseases, with the probable exception of IgA

nephropathy (6). The shared associations instead reflect processes that lead to change in both

immune-mediated disease risk and immunoglobulin levels. Our results also provide a cautionary

tale for the use of genetic correlation more generally: weak or absent genetic correlation, as with

lymphocyte counts, should not be taken as a dispositive indicator of genetic independence, and

positive genetic correlation may be consistent with the presence of shared causal variants which

nonetheless exert discordant effects on each phenotype.

We have presented an expanded view of the genetic architecture of serum antibody production.

This view will be broadened still further by the adoption of modern high-throughput affinity-

based proteomics techniques, such as the 'SomaScan' DNA aptamer-based method used to

generate the Pietzner and Eldjarn datasets included in our meta-analyses (83). These methods

allow many proteins to be assayed in parallel and should make the measurement of serum

proteins in large, biobank-sized cohorts affordable (84). Investigation of the pattern of shared

genetic effects on lymphocyte abundance and antibody production, and the seemingly

paradoxical disagreement in the direction of variant effects upon them, was hindered by the lack

of large, publicly available B and T cell-specific phenotype GWAS. Should such datasets

become accessible, their use in colocalisation analysis should prove insightful as to the extent

to which variants mediate their effect on serum antibody levels through proximal effects on

lymphocyte abundance. The composite nature of the lymphocyte count phenotype in the

available dataset prevented investigation of the causal effect of the abundance of B cells (or of

relevant T helper cell subsets) on serum antibody production through Mendelian randomisation.

B-cell lymphopaenia underlies hypo- and agammaglobulinaemia in a number of antibody

deficiencies, such as Bruton's agammaglobulinaemia and some CVID-like disorders such as

TRNT1 deficiency (35). This suggests smaller genetic effects on B cell abundance mediated by

common variants might also underlie variation in serum antibody production in the

normophysiological setting.

We meta-analysed GWAS conducted almost exclusively in individuals of European ancestry,

the sole exception being the trans-ancestry GWAS of serum IgA by Liu et al. We were thus not

able to investigate the extent to which the genetic architecture of serum antibody production

varies across ancestries or the replicability of our discoveries across populations. Whilst GWAS

of antibody phenotypes in East Asian ancestries have been published (8,85), their summary

statistics are not publicly available for meta-analysis, a common obstacle in GWAS meta-

analysis (86).

As well as IMDs generally, our results are relevant to the study of the antibody deficiencies,

particularly the two most common, selective IgA deficiency and common variable

immunodeficiency (3). The genetic aetiology of these diseases remains obscure in most

patients and there is evidence of a common-variant contribution to both (10,87,88). They are

therefore good candidates for joint genetic analysis with the meta-analyses we publish here.

Such an analysis could address the hypothesis of whether inheritance of a preponderance of

common hypomorphic serum antibody-associated variants could account for clinical antibody

deficiency in cases where a Mendelian pattern of disease or known monogenic causal variant

are absent.

579 Data and code availability

GWAS summary statistics have been deposited at the following Zenodo URL:

https://doi.org/10.5281/zenodo.17010403.

We have made available the code used to produce the results presented here in the form of a

snakemake (89) pipeline (doi: 10.5281/zenodo.18023612):

https://github.com/twillis209/serum_ig_pipeline. The standalone *snakemake* pipeline used to

process 1kGP data is also available: https://github.com/twillis209/1kGP_pipeline.

Acknowledgements

We would like to acknowledge the participants of the Fenland Study (doi: 10.22025/2017.10.101.00001). We thank Christopher Benson, Debora Lucarelli, and Jing Hua Zhao for their contribution to the generation of data used in this paper. We wish to acknowledge all GWAS participants for their contribution to the data used herein. We also acknowledge the investigators who carried out these GWAS and made their summary statistics publicly available. We are grateful to all the participants of the EPIC-Norfolk study and to the many members of the study teams at the University of Cambridge who have enabled this research.

Author contributions

Thomas W. Willis: Writing – review & editing, Writing – original draft, Visualization, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Effrossyni Gkrania-Klotsas: Writing – review & editing, Methodology, Investigation, Funding acquisition, Data curation. Nicholas J. Wareham: Writing – review & editing, Funding acquisition, Data curation. Eoin F. McKinney: Writing – review & editing, Data curation. Paul A. Lyons: Writing – review & editing, Funding acquisition, Data curation. Kenneth G.C. Smith: Writing – review & editing, Funding acquisition. Chris Wallace: Writing – review & editing, Writing – original draft, Visualization, Supervision, Software, Methodology, Investigation, Funding acquisition, Formal analysis, Conceptualization.

Conflicts of Interest

CW is a part time employee of GSK. GSK had no role in this study or its publication.

Funding

This work was supported by the Wellcome Trust (WT107881, WT219506) and the Medical Research Council (MC_UU_00002/4, MC_UU_00040/01).

The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1, MC-UU_12015/1, and MC_UU_00006/1) and Cancer Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by the Medical Research Council (MC_PC_13048). We also acknowledge funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement 633964 (ImmunoAgeing).

For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Bibliography

1. Hatagima A, Cabello PH, Krieger H. Causal analysis of the variability of IgA, IgG, and IgM immunoglobulin levels. Hum Biol. 1999;71(2):219–29.

2. Bruton OC. AGAMMAGLOBULINEMIA. Pediatrics. 1952 Jun;9(6):722–8.

3. Pan-Hammarström Q, Hammarström L. Antibody Deficiency Diseases. Eur J Immunol. 2008;38(2):327–33.

4. Yazdani R, Fekrvand S, Shahkarami S, Azizi G, Moazzami B, Abolhassani H, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol. 2019 Jan 1;198:19–30.

5. Viktorin A, Frankowiack M, Padyukov L, Chang Z, Melén E, Sääf A, et al. IgA measurements in over 12 000 Swedish twins reveal sex differential heritability and regulatory locus near CD30L. Hum Mol Genet. 2014 Aug 1;23(15):4177–84.

6. Liu L, Khan A, Sanchez-Rodriguez E, Zanoni F, Li Y, Steers N, et al. Genetic Regulation of Serum IgA Levels and Susceptibility to Common Immune, Infectious, Kidney, and Cardio-Metabolic Traits. Nat Commun. 2022 Nov;13(1):6859.

7. Bian S, Guo X, Yang X, Wei Y, Yang Z, Cheng S, et al. Genetic determinants of IgG antibody response to COVID-19 vaccination. Am J Hum Genet. 2024 Jan 4;111(1):181–99.

8. Yang M, Wu Y, Lu Y, Liu C, Sun J, Liao M, et al. Genome-wide scan identifies variant in TNFSF13 associated with serum IgM in a healthy Chinese male population. PLoS One. 2012 Oct 31;7(10):e47990.

9. Kim JH, Cheong HS, Park JS, Jang AS, Uh ST, Kim YH, et al. A genome-wide association study of total serum and mite-specific IgEs in asthma patients. PLoS One. 2013 Aug 13;8(8):e71958.

10. Willis TW, Gkrania-Klotsas E, Wareham NJ, McKinney EF, Lyons PA, Smith KGC, et al. Leveraging pleiotropy identifies common-variant associations with selective IgA deficiency. Clin Immunol. 2024 Nov 1;268(110356):110356.

11. Dennis JK, Sealock JM, Straub P, Lee YH, Hucks D, Actkins K 'era, et al. Clinical Laboratory Test-Wide Association Scan of Polygenic Scores Identifies Biomarkers of Complex Disease. Genome Med. 2021 Jan;13(1):6.

12. Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018 Jul 27;10(1):59.

13. Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023 Oct 4;622(7982):348–58.

14. Pietzner M, Wheeler E, Carrasco-Zanini J, Cortes A, Koprulu M, Wörheide MA, et al. Mapping the proteo-genomic convergence of human diseases. Science. 2021 Nov 12;374(6569):eabj1541.

15. Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers
G, et al. Identification of Sequence Variants Influencing Immunoglobulin Levels. Nat Genet.
2017 Aug;49(8):1182–91.

16. Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, et al. An International Genome-
Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs. J
Hepatol. 2021 Sep;75(3):572–81.

17. Ji SG, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, et al. Genome-Wide
Association Study of Primary Sclerosing Cholangitis Identifies New Risk Loci and
Quantifies the Genetic Relationship with Inflammatory Bowel Disease. Nat Genet. 2017
Feb;49(2):269–73.

18. Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al. Multi-Ancestry
Genome-Wide Association Analyses Identify Novel Genetic Mechanisms in Rheumatoid
Arthritis. Nat Genet. 2022 Nov;54(11):1640–51.

19. Bentham J, Morris DL, Cunninghame Graham DS, Pinder CL, Tombleson P, Behrens TW,
et al. Genetic Association Analyses Implicate Aberrant Regulation of Innate and Adaptive
Immunity Genes in the Pathogenesis of Systemic Lupus Erythematosus. Nat Genet. 2015
Dec;47(12):1457–64.

20. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-Wide
Association Study Implicates Immune Activation of Multiple Integrin Genes in Inflammatory
Bowel Disease. Nat Genet. 2017 Feb;49(2):256–61.

21. Chiou J, Geusz RJ, Okino ML, Han JY, Miller M, Melton R, et al. Interpreting Type 1
Diabetes Risk with Genetics and Single-Cell Epigenomics. Nature. 2021
Jun;594(7863):398–402.

22. INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM. Multiple Sclerosis
Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility. Science.
2019 Sep;365(6460):eaav7188.

23. Pasanen A, Sliz E, Huilaja L, FinnGen, Estonian Biobank Research Team, Reimann E, et
al. Identifying atopic dermatitis risk loci in 1,094,060 individuals with subanalysis of disease
severity and onset. J Invest Dermatol. 2024 Nov;144(11):2417–25.

24. Figuerêdo J, Krebs K, Pujol-Gualdo N, Haller T, Võsa U, Volke V, et al. Uncovering the
shared genetic components of thyroid disorders and reproductive health. Eur J Endocrinol.
2024 Aug 5;191(2):211–22.

25. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense Genotyping
Identifies and Localizes Multiple Common and Rare Variant Association Signals in Celiac
Disease. Nat Genet. 2011 Dec;43(12):1193–201.

26. Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al. Genome-
wide association analyses define pathogenic signaling pathways and prioritize drug targets
for IgA nephropathy. Nat Genet. 2023 Jul;55(7):1091–105.

27. Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-Ethnic
and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global
Populations. Cell. 2020 Sep;182(5):1198–213.e14.

28. Cerezo M, Sollis E, Ji Y, Lewis E, Abid A, Bircan KO, et al. The NHGRI-EBI GWAS Catalog: standards for reusability, sustainability and diversity. Nucleic Acids Res. 2025 Jan 6;53(D1):D998–1005.

29. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-Generation PLINK: Rising to the Challenge of Larger and Richer Datasets. Gigascience. 2015 Dec;4(1):s13742–015 – 0047–8.

30. Purcell S, Chang C. PLINK 2.0.

31. Singh A, Southam L, Hatzikotoulas K, Rayner NW, Suzuki K, Taylor HJ, et al. Correcting for genomic inflation leads to loss of power in large-scale genome-wide association study meta-analysis. Genet Epidemiol. 2025 Sep 6;49(6):e70016.

32. Lewis MJ, Wang S. locuszoomr: an R package for visualizing publication-ready regional gene locus plots. Bioinform Adv. 2024 Dec 26;5(1):vbaf006.

33. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015 Nov 1;31(21):3555–7.

34. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nat Commun. 2022 Jan 25;13(1):480.

35. Poli MC, Aksentijevich I, Bousfiha AA, Cunningham-Rundles C, Hambleton S, Klein C, et al. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. Journal of Human Immunity [Internet]. 2025 May 5 [cited 2025 Aug 10];1(1). Available from: http://dx.doi.org/10.70962/jhi.20250003

36. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009 Jul 23;4(8):1184–91.

37. Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005 Aug 15;21(16):3439–40.

38. Speed D, Balding DJ. SumHer Better Estimates the SNP Heritability of Complex Traits from Summary Statistics. Nat Genet. 2019 Feb;51(2):277–84.

39. A Global Reference for Human Genetic Variation. Nature. 2015 Oct;526(7571):68–74.

40. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High Coverage Whole Genome Sequencing of the Expanded 1000 Genomes Project Cohort Including 602 Trios. bioRxiv. 2021 Feb;2021.02.06.430068.

41. Buniello A, Suveges D, Cruz-Castillo C, Llinares MB, Cornu H, Lopez I, et al. Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Res. 2025 Jan 6;53(D1):D1467–75.

42. Dyer SC, Austine-Orimoloye O, Azov AG, Barba M, Barnes I, Barrera-Enriquez VP, et al. Ensembl 2025. Nucleic Acids Res. 2025 Jan 6;53(D1):D948–57.

43. Yu G. Thirteen years of clusterProfiler. Innovation (Camb). 2024 Nov 4;5(6):100722.

44. Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis
and visualization. Mol Biosyst. 2016 Feb 26;12(2):477–9.

45. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using
Summary Statistics. PLoS Genet. 2014 May;10(5):e1004383.

46. Wakefield J. Bayes factors for genome-wide association studies: comparison with P-values.
Genet Epidemiol. 2009 Jan 1;33(1):79–86.

47. Kanai M, Elzur R, Zhou W, Global Biobank Meta-analysis Initiative, Daly MJ, Finucane HK.
Meta-analysis fine-mapping is often miscalibrated at single-variant resolution. Cell Genom.
2022 Dec 14;2(12):100210.

48. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for
immunogenicity. MAbs. 2009 Jul;1(4):332–8.

49. Purcell RA, Aurelia LC, Esterbauer R, Allen LF, Bond KA, Williamson DA, et al.
Immunoglobulin G genetic variation can confound assessment of antibody levels via altered
binding to detection reagents. Clin Transl Immunology. 2024 Feb 29;13(3):e1494.

50. Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B. The hematopoiesis-specific GTP-binding
protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an
inhibitory function. Mol Cell Biol. 2002 Feb;22(4):1158–71.

51. Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnana V, et al. Human RHOH
deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012
Sep 4;122(9):3239–47.

52. Dorn T. Analysis of RhoH function in vivo [Internet] [Doctoral dissertation]. [Ludwig-
Maximiliansuniversitaet Muenchen]: Ludwig-Maximiliansuniversitaet Muenchen; 2007.
Available from: https://edoc.ub.uni-muenchen.de/7457/1/Dorn_Tatjana.pdf

53. Liu Z, Liu Y, Li T, Wang P, Mo X, Lv P, et al. CMTM7 plays key roles in TLR-induced
plasma cell differentiation and p38 activation in murine B-1 B cells. Eur J Immunol. 2020
Jun 1;50(6):809–21.

54. Chen Z, Krinsky A, Woolaver RA, Wang X, Chen SMY, Popolizio V, et al. TRAF3 acts as a
checkpoint of B cell receptor signaling to control antibody class switch recombination and
anergy. J Immunol. 2020 Aug 1;205(3):830–41.

55. Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, et al. GWAS for serum galactose-
deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017
Feb 10;13(2):e1006609.

56. Liu L, Shen A, Taylor AD, Atlas Khan, Reily C, Hall SD, et al. Genome-wide association
study (GWAS) of serum galactose-deficient IgA1 uncovers shared genetic determinants
with IgAN: Th-po0633. J Am Soc Nephrol. 2025 Oct;36(10S):10.1681/ASN.2025pyp4sfbe.

57. Fütterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K. The lymphotoxin β receptor controls
organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity. 1998
Jul;9(1):59–70.

58. Eyre S, Hinks A, Bowes J, Flynn E, Martin P, Wilson AG, et al. Overlapping Genetic
Susceptibility Variants between Three Autoimmune Disorders: Rheumatoid Arthritis, Type 1
Diabetes and Coeliac Disease. Arthritis Res Ther. 2010 Sep;12(5):R175.

59. Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell
development and leukemogenesis. Adv Immunol. 2011;111:179–206.

60. Kaiser FMP, Gruenbacher S, Oyaga MR, Nio E, Jaritz M, Sun Q, et al. Biallelic PAX5
mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum
disorder. J Exp Med [Internet]. 2022 Sep 5 [cited 2025 Feb 21];219(9). Available from:
https://rupress.org/jem/article-pdf/219/9/e20220498/1916562/jem_20220498.pdf

61. Ackermann JA, Nys J, Schweighoffer E, McCleary S, Smithers N, Tybulewicz VLJ. Syk
tyrosine kinase is critical for B cell antibody responses and memory B cell survival. J
Immunol. 2015 May 15;194(10):4650–6.

62. Wang L, Aschenbrenner D, Zeng Z, Cao X, Mayr D, Mehta M, et al. Gain-of-function
variants in SYK cause immune dysregulation and systemic inflammation in humans and
mice. Nat Genet. 2021 Apr 29;53(4):500–10.

63. Kury P, Staniek J, Wegehaupt O, Janowska I, Eckenweiler M, Korinthenberg R, et al.
Agammaglobulinemia with Normal B-cell Numbers in a Patient Lacking Bob1. J Allergy Clin
Immunol. 2021 May;147(5):1977–80.

64. Guldenpfennig C, Teixeiro E, Daniels M. NF-kB's contribution to B cell fate decisions. Front
Immunol. 2023 Jul 18;14:1214095.

65. Tuijnenburg P, Lango Allen H, Burns SO, Greene D, Jansen MH, Staples E, et al. Loss-of-
Function Nuclear Factor κB Subunit 1 (NFKB1) Variants Are the Most Common Monogenic
Cause of Common Variable Immunodeficiency in Europeans. J Allergy Clin Immunol. 2018
Oct;142(4):1285–96.

66. Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena
MT, et al. International Consensus Document (ICON): Common Variable Immunodeficiency
Disorders. J Allergy Clin Immunol Pract. 2016 Jan;4(1):38–59.

67. Kaiser FMP, Janowska I, Menafra R, de Gier M, Korzhenevich J, Pico-Knijnenburg I, et al.
IL-7 receptor signaling drives human B-cell progenitor differentiation and expansion. Blood.
2023 Sep 28;142(13):1113–30.

68. Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell
proliferation by facilitating B cell receptor-Ras signaling. J Immunol. 2005 Dec
1;175(11):7179–84.

69. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism
and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009
May;229(1):152–72.

70. Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel D, Graness A, et al. Tumor
necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-
mediated NF-kappaB activation. J Biol Chem. 2004 Jan 2;279(1):677–85.

71. Lin L, Lin G, Lin H, Chen L, Chen X, Lin Q, et al. Integrated profiling of endoplasmic
reticulum stress-related DERL3 in the prognostic and immune features of lung

adenocarcinoma. Front Immunol. 2022 Oct 7;13:906420.

72. Landini A, Trbojević-Akmačić I, Navarro P, Tsepilov YA, Sharapov SZ, Vučković F, et al.
Genetic regulation of post-translational modification of two distinct proteins. Nat Commun.
2022 Mar 24;13(1):1586.

73. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, et al. Genetics of
35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021 Feb 18;53(2):185–94.

74. Hong R, Lai N, Ouchida R, Xiong E, Zhou Y, Min Q, et al. The B cell novel protein 1
(BCNP1) regulates BCR signaling and B cell apoptosis. Eur J Immunol. 2019
Jun;49(6):911–7.

75. Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 mutations
drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. Cell. 2020 Jul
23;182(2):297–316.e27.

76. Scott DW, Mungall KL, Ben-Neriah S, Rogic S, Morin RD, Slack GW, et al. TBL1XR1/TP63:
a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood. 2012 May
24;119(21):4949–52.

77. Asmar F, Fog CK, Jensen K, Jacobsen L, Ralfkiær E, Geisler CH, et al. PRDM11 is a novel
putative tumor suppressor in aggressive B Cell Lymphoma. Blood. 2010 Nov
19;116(21):1002–1002.

78. Rodriguez OL, Safonova Y, Silver CA, Shields K, Gibson WS, Kos JT, et al. Genetic
variation in the immunoglobulin heavy chain locus shapes the human antibody repertoire.
Nat Commun. 2023 Jul 21;14(1):4419.

79. Engelbrecht E, Rodriguez OL, Lees W, Vanwinkle Z, Shields K, Schultze S, et al. Germline
polymorphisms in the immunoglobulin kappa and lambda loci underpinning antibody light
chain repertoire variability. Nat Commun. 2025 Nov 28;16(1):11707.

80. Olafsdottir TA, Thorleifsson G, Lopez de Lapuente Portilla A, Jonsson S, Stefansdottir L,
Niroula A, et al. Sequence variants influencing the regulation of serum IgG subclass levels.
Nat Commun. 2024 Sep 14;15(1):8054.

81. Corcoran M, Narang S, Kaduk M, Chernyshev M, Färnert A, Sundling C, et al. Human IGH
germline gene diversity and allele frequencies in 2486 individuals from 25 global
populations delineated by ultra-high throughput genotyping [Internet]. bioRxiv. bioRxiv;
2025 [cited 2026 Jan 8]. p. 2025.08.06.668935. Available from:
https://www.biorxiv.org/content/10.1101/2025.08.06.668935v1.abstract

82. Watson CT, Collins AM, Ohlin M, Heather JM, Peres A, Lees WD, et al. Building
immunoglobulin and T cell receptor gene databases for the future. Immunoinformatics
(Amst). 2025 Sep 1;19(100059):100059.

83. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale
with the SOMAscan proteomics platform. N Biotechnol. 2012 Jun 15;29(5):543–9.

84. Largest proteome study enlists 14 biopharmas. Nat Biotechnol. 2025 Feb 14;43(2):153.

85. Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic
analysis of quantitative traits in the Japanese population links cell types to complex human

diseases. Nat Genet. 2018 Mar 5;50(3):390–400.

86. Reales G, Wallace C. Sharing GWAS Summary Statistics Results in More Citations.
Communications Biology. 2023 Jan;6(1):1–6.

87. Li J, Jørgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, et al. Association of
CLEC16A with Human Common Variable Immunodeficiency Disorder and Role in Murine B
Cells. Nat Commun. 2015 Apr;6:6804.

88. Bronson PG, Chang D, Bhangale T, Seldin MF, Ferreira RC, Urcelay E, et al. Common
Variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A Are Associated with Selective IgA
Deficiency. Nat Genet. 2016 Nov;48(11):1425–9.

89. Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al.
Sustainable Data Analysis with Snakemake. F1000Res [Internet]. 2021 Apr [cited 2022 Sep
27];10(33). Available from: http://dx.doi.org/10.12688/f1000research.29032.2

90. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment
tool for interpreting omics data. Innovation (Camb). 2021 Aug 28;2(3):100141.

881 Table legends

Table 1. Lead SNPs from novel genome-wide significant associations in the IgA, IgG, and IgM
meta-analyses. 'MAF' is the minor allele frequency computed from data in the component
GWAS where this information was provided in the original studies. 'Gene(s)' gives the gene(s)
with the most evidence linking it/them to the association signal; the procedure by which we
assigned genes to variants, and identified quantitative trait loci (QTL) and missense variants is
described in Methods. 'Missense gene' reports the gene (if any) in which the lead SNP was
identified to be a missense variant. 'Q' is Cochran's Q test statistic for which the degrees of
freedom are also given. 'I2' is the I^2 statistic.
890

891 **Table 2.** Estimates of the genetic correlation between serum antibody isotype levels. p-values
892 were calculated from a chi-squared test of non-zero genetic correlation. The MHC and *IGH*,
893 *IGK*, and *IGL* loci were excluded from the datasets used to produce these estimates.